Emergent BioSolutions (EBS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for April 29, 2026, with voting open to shareholders of record as of March 6, 2026.
Shareholders are encouraged to review the proxy statement and related SEC filings for detailed information on proposals.
Voting matters and shareholder proposals
Investors will vote on several important proposals at the annual meeting.
Voting instructions are distributed via email or brokerage portals, with a deadline of April 28, 2026.
Shareholder rights and capital structure
Only shareholders holding shares as of March 6, 2026, are eligible to participate in the voting process.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Emergent BioSolutions
- Annual meeting on April 29, 2026; eligible shareholders urged to vote by proxy.EBS
Proxy filing16 Apr 2026 - Proxy covers director elections, auditor ratification, pay, and equity plan amendment.EBSProxy filing20 Mar 2026
- Key votes include director elections, auditor ratification, and stock plan amendment.EBSProxy filing20 Mar 2026
- 2025 saw a profitable turnaround with $743M revenue, margin gains, and lower leverage.EBSQ4 202526 Feb 2026
- Q2 revenues beat guidance, but net loss widened; FY 2024 outlook and debt reduction targets raised.EBSQ2 20242 Feb 2026
- Revenue and EBITDA surged as Narcan and MCM products expand, fueling a strategic turnaround.EBSH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Q3 2024 net income hit $114.8M as revenue rose 9% and guidance was raised.EBSQ3 202416 Jan 2026
- Transformation boosts profitability, debt reduction, and innovation in biodefense and naloxone.EBS44th Annual J.P. Morgan Healthcare Conference15 Jan 2026
- Turnaround accelerates with debt cuts, asset sales, and expanded naloxone and MCM portfolios.EBS43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026